AletaBio
@BioAleta
Followers
125
Following
1
Media
5
Statuses
22
Aleta Biotherapeutics announces ALETA-001 Presentation at 63rd ASH Annual Meeting https://t.co/fIf9bn8ahh cc @CR_UK #lymphoma #leukemia #celltherapy
businesswire.com
Aleta Biotherapeutics announces a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
0
1
1
Aleta Biotherapeutics announces ALETA-001 Presentation at 63rd ASH Annual Meeting https://t.co/fIf9bn8ahh cc @CR_UK #lymphoma #leukemia #celltherapy
businesswire.com
Aleta Biotherapeutics announces a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
0
1
1
we'll discuss triple antigen targeting for solid tumor therapy - and the power of immune architecture - at #SITC21
https://t.co/73Bu8TRZwC
@BioAleta
businesswire.com
Aleta Biotherapeutics to Present at Society for Immunotherapy of Cancer
0
0
0
The Fall Conference Season starts off with the virtual CAR-TCR Summit next week. Join our President and CSO Paul Rennert as he chairs a Clinical Session on Wednesday at noon EST then jumps into the Start-Up Strategy Panel at 4pm EST! @BioAleta @CAR_TCell
0
2
3
This new paper from the @BioAleta labs reveals a biparatopic anti-CLEC12A CAR T Engager protein, and introduces a dual-CAR T Engager that targets CLEC12A and CD33 https://t.co/vHcdc1E9BZ…
#celltherapy #immunotherapy #AML #leukemia @MCT_AACR
0
1
3
Sending hearty congratulations to the Advent Life Sciences team on their closing of two new funds! Great investors, great friends. https://t.co/22CWL9tRLo.
0
1
1
Aleta Bio will also be represented at the Oncology Cell Therapy Summit where I will join a town hall discussion on the challenges posed by Tumor Microenvironments - with @ChrisHeery from Precision and Christina Coughlin from Rubius https://t.co/I0l9u02yRw
0
3
4
Aleta Bio is Online this week at the B. Riley Oncology Investor Conference. We are in good company - a great line up of public and private companies presenting. https://t.co/6Wa6iRcFU3
0
2
2
The #SITC2020 virtual poster walks start this evening with our poster on a cell therapy carefully designed to treat Her2-positive breast and lung cancer patients relapsing with brain metastases without having to stop their biologic treatment - a huge win for patients
0
2
1
So, @bioaleta we understand the complexity of CAR T cell engineering. A new paper gave us a lot to think about, reviewed here: https://t.co/qLiIqGaMMy
0
3
9
Aleta Biotherapeutics news: Come hear our #ASH19 talk on a novel therapeutic to counter relapses in ALL & NHL patients treated with CD19 CAR-T cells. Half of these patients relapse in under a year, our goal is to rescue them. https://t.co/vuUhHYrtW6
#celltherapy #immunotherapy
0
1
1
Aleta Biotherapeutics news: Come hear our #ASH19 talk on a novel therapeutic to counter relapses in ALL & NHL patients treated with CD19 CAR-T cells. Half of these patients relapse in under a year, our goal is to rescue them. https://t.co/vuUhHYrtW6
https://t.co/cwBjZCf19G
0
1
2
Aleta Biotherapeutics news: Come hear our talk on a novel therapeutic to counter relapses in ALL & NHL patients treated with CD19 CAR-T cells. Half of these patients relapse in under a year, our goal is to rescue them. #ASH19
https://t.co/cwBjZCf19G
https://t.co/vuUhHYrtW6
0
2
1
Aleta Biotherapeutics news: Come hear our talk on a novel therapeutic to counter relapses in ALL & NHL patients treated with CD19 CAR-T cells. Half of these patients relapse in under a year, our goal is to rescue them. #ASH19
https://t.co/cwBjZCf19G
https://t.co/vuUhHYrtW6
0
2
1
0
2
4
Aleta Bio seeking a science/medical writer/program manager to help us drive our cell therapy programs into the clinic part time/semi-remote/metro-west Boston and you get to work with @PDRennert !!! how cool is that...
1
5
5
Aleta Biotherapeutics' will present preclinical date at #SITC18 showing robust tumor cytotoxicity across diverse IMPACT cell therapy programs. Aleta develops multi-antigen targeting solutions for Her2+ solid tumors, AML and B cell malignancies: poster #11102 by @pdrennert et al
0
4
7
1
4
5